Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL310 versus idursulfase in pediatric Hunter syndrome
ISRCTN11652897Phase 3Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jul 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of tividenofusp alfa and idursulfase in mucopolysaccharidosis type 2 (4 cohorts), sponsored by Denali Therapeutics Inc. Started Jul 2022; status: completed.
02
Drugs
tividenofusp alfaidursulfase
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on ISRCTN11652897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11652897.